





Supplementary Figure 1. Matriptase expression is retained in LEKTI-deficient epidermis. Skin sections from newborn LEKTI- and matriptase-sufficient (*Spink5*⁺; *St14*⁺) (a), LEKTI-deficient (*Spink5*^{-/-}; *St14*⁺) (b), and matriptase-deficient (*Spink5*⁺; *St14*^{-/-}) (c) mice were immunostained with antibodies against matriptase. Matriptase expression is retained in the suprabasal epidermis of LEKTI-deficient skin. Size bar, 25 μ m.



Supplementary Figure 2. Prostasin is not an efficient activator of epidermal pro-kallikrein-related peptidases. Recombinant pro-kallikrein-related peptidase 5 (8 nM) or pro-kallikrein-related peptidase 7 (0.4 mM) were incubated for 30 min with and without 0.4 mM recombinant prostasin. The fluorogenic kallikrein-selective peptide Boc-Val-Pro-Arg-AMC was then added and fluorescence development was recorded over time. Low hydrolytic activity and additive effects of mixing prostasin with pro-kallikrein-related peptidase 5 are observed. The experiment was performed in triplicate and data are shown as mean fluorescence \pm standard error of the mean.



Supplementary Figure 3. Epidermal *in situ* proteolytic activity is inhibited by recombinant LEKTI. Skin cryosections (5 μM) from newborn wildtype mice were incubated either with buffer (a), with fluorescence-quenched casein alone (b) or with fluorescence-quenched casein and 5 μM of recombinant LEKTI D6-9 (c). The proteolytic activity was strongly inhibited upon the addition of recombinant LEKTI.



Supplementary Figure 4. Loss of matriptase restores profilaggrin granules and blocks excessive profilaggrin processing in LEKTI-deficient epidermis. Combined profilaggrin/filaggrin (green) and basal-layer marker $\alpha 6$ -integrin (red) immunofluorescence of epidermis from newborn LEKTI- and matriptase-sufficient (*Spink5*⁺;*St14*⁺) (**a**), LEKTI-deficient (*Spink5*^{-/-};*St14*⁺) (**b**), matriptase-deficient (*Spink5*⁺;*St14*^{-/-}) (**c**), and combined LEKTI- and matriptase-deficient (*Spink5*^{-/-};*St14*^{-/-}) (**d**) mice. Profilaggrin-granules in LEKTI-sufficient epidermis (examples with arrows in inset in **a**) are absent in LEKTI-deficient epidermis (inset in **b**), but are restored after simultaneous matriptase ablation (examples with arrows in inset in **d**). Size bars all frames, 50 μ m. (**e**) Profilaggrin/filaggrin Western blot and (**f**) Coomassie brilliant blue staining of epidermal extracts from newborn LEKTI and matriptase-sufficient (*Spink5*⁺;*St14*⁺) (lanes 1 and 5), LEKTI-deficient (*Spink5*^{-/-};*St14*⁺) (lanes 2 and 6), matriptase-deficient (*Spink5*⁺;*St14*^{-/-}) (lanes 3 and 7), and combined LEKTI and matriptase-deficient (*Spink5*^{-/-};*St14*^{-/-}) (lanes 4 and 8) mice from a single litter of mice, showing that excessive proteolytic processing of profilaggrin in LEKTI-deficient epidermis is blocked by simultaneous matriptase deficiency. Molecular weight standards (kDa) are indicated at left and the position of processed filaggrin monomer (FG) is indicated at right.

